I am a cardiologist with advanced training in heart failure medicine, clinical investigation, and applied genomics. My laboratory studies mechanisms of heart failure in human subjects using whole genome expression profiling, computational biology, molecular biology, and epidemiology. Using these approaches, we provided the first evidence that transcription factors identified in the murine heart contribute to heart failure in humans and found a previously unsuspected role for forkhead (FOX) transcription factors in human heart failure. We have also pioneered clinical applications of expression profiling, including the first study to demonstrate that blood gene expression can serve as a noninvasive biomarker of cardiac allograft rejection. We have since expanded our approaches to include SNP-association studies in large NHLBI consortia (CARe and SHARe), by recruiting large referral cohorts of patients with advanced heart failure, and by performing follow-up studies in transgenic mice.
Selected Publications
Testani JM, McCauley BD, Chen J, Coca SG, Cappola TP, Kimmel SE: Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure. J Card Fail 17(12): 993-1000, Dec 2011.
Testani JM, Coca SG, Shannon RP, Kimmel SE, Cappola TP: Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials. Eur J Heart Fail 13(11): 1224-30, Nov 2011.
Barth AS, Kumordzie A, Frangakis C, Margulies KB, Cappola TP, Tomaselli GF: Reciprocal transcriptional regulation of metabolic and signaling pathways correlates with disease severity in heart failure. Circ Cardiovasc Genet 4(5): 475-83, Oct 2011.
Jessup M, Greenberg B, Mancini D, Cappola TP, Pauly DF, Jaski B, Alex Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ: CUPID - a phase 2 trial of intracoronary gene therapy of sarcoplasmic
reticulum Ca2+ ATPase (SERCA2a) in patients with advanced heart failure. Circulation 124(3): 304-313, July 2011.
Ky B, French B, Ruparel K, Sweitzer NK, Fang JC, Levy WC, Sawyer DB, Cappola TP: The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J Am Coll Cardiol 58(4): 395-401, July 2011.
Testani J, Cappola TP, Brensinger C, Shannon RP, Kimmel S: Interaction between loop-diuretic associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol 58(4): 375-382, July 2011.
Trivedi CM, Cappola TP, Margulies KB, Epstein JA: Homeodomain only protein X is down-regulated in human heart failure
J Mol Cell Cardiol 50(6): 1056-8, June 2011.
Testani JM, Cappola TP, McCauley BD, Chen J, Shen J, Shannon RP, Kimmel SE: Impact of worsening renal function during the treatment of decompensated heart failure on changes in renal function during subsequent hospitalization
Am Heart J 161(5): 944, May 2011.
Ky, French BC, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AHB, Fang JC, Boxer R, Sweitzer NK, Levy W, Goldberg LR, Jessup M, Cappola TP: High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 4(2): 180-187, Mar 2011.
Cappola TP, Matkovich SJ, Wang W, van Booven D, Li M, Wang W, Qu L, Sweitzer NK, Fang J, Reilly MP, Hakonarson H, Nerbonne JM, Dorn II GW: A loss-of-function DNA sequence variant in CLCNKA implicates the cardio-renal axis in inter-individual heart failure risk variation. Proc Natl Acad Sci USA 108(6): 2456-61, Feb 2011.
back to top
Last updated: 02/20/2012
The Trustees of the University of Pennsylvania
